FDA clears CMS' I-Beam positioning system
CMS Inc. has received FDA 510(k) clearance for its I-Beam mobile patient positioning system that uses ultrasound and other images to locate target organs or tumors.
I-Beam uses a 3D positioning technology with an integrated camera and free hand ultrasound probe that is registered through a passive localization target inserted in the shadow or wedge tray of a linear accelerator. This technology allows I-Beam to be self-contained without the need for hardware mounting in the treatment room.
CMS is based in St. Louis, Mo., and develops and supports radiation treatment software. The company estimates that it has more than 1,400 treatment planning systems installed worldwide.
I-Beam uses a 3D positioning technology with an integrated camera and free hand ultrasound probe that is registered through a passive localization target inserted in the shadow or wedge tray of a linear accelerator. This technology allows I-Beam to be self-contained without the need for hardware mounting in the treatment room.
CMS is based in St. Louis, Mo., and develops and supports radiation treatment software. The company estimates that it has more than 1,400 treatment planning systems installed worldwide.